The genetic landscape of anaplastic pleomorphic xanthoastrocytoma
暂无分享,去创建一个
M. Berger | A. Bollen | B. Bastian | S. Mueller | T. Tihan | J. Phillips | D. Solomon | C. Kline | A. Perry | M. Pekmezci | N. Gupta | J. Grenert | J. V. Van Ziffle | J. Shieh | T. Nicolaides | N. Joseph | A. Banerjee | H. Lee | Henry Z. Gong | Katharine Chen | J. Van Ziffle | Joseph T C Shieh | N. Gupta | N. Gupta
[1] David T. W. Jones,et al. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis , 2018, Brain pathology.
[2] Hideo Nakamura,et al. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity , 2018, Brain pathology.
[3] F. Rodriguez,et al. Recurrent copy number alterations in low‐grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation , 2018, Brain pathology.
[4] M. Xing,et al. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer , 2018, Nature Communications.
[5] K. Ligon,et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Nobusawa,et al. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low‐grade astrocytoma , 2017, Neuropathology : official journal of the Japanese Society of Neuropathology.
[7] Tao Zhang,et al. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality , 2017, JAMA oncology.
[8] Arie Perry,et al. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy , 2016, Neuro-oncology.
[9] D. Wheeler,et al. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. , 2016, Blood.
[10] F. Rodriguez,et al. Frequent alternative lengthening of telomeres and ATRX loss in adult NF1-associated diffuse and high-grade astrocytomas , 2016, Acta Neuropathologica.
[11] A. Bollen,et al. Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation , 2016, Acta Neuropathologica.
[12] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[13] Eric Talevich,et al. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..
[14] S. Patil,et al. Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas—Same Entity or First Cousins? , 2016, Brain pathology.
[15] Roland Eils,et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.
[16] Hanlee P. Ji,et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.
[17] R. Dummer,et al. The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.
[18] P. Burger,et al. Pleomorphic Xanthoastrocytoma: Natural History and Long‐Term Follow‐Up , 2015, Brain pathology.
[19] Alexander R. Pico,et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.
[20] Chibo Hong,et al. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer , 2015, Science.
[21] Arie Perry,et al. CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas , 2015, Journal of neuropathology and experimental neurology.
[22] D. Merico,et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] David T. W. Jones,et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers , 2015, Acta Neuropathologica.
[24] J. Bishop,et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Satoshi O. Suzuki,et al. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation , 2014, Brain Tumor Pathology.
[26] A. Becker,et al. BRAF‐Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and CD34 Expression , 2014, Brain pathology.
[27] David T. W. Jones,et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system , 2013, Acta Neuropathologica.
[28] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[29] M. O. de Moraes Filho,et al. CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex. , 2013, International journal of surgery.
[30] D. Aisner,et al. Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation , 2013, The American journal of surgical pathology.
[31] Heather L. Mulder,et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.
[32] Gary L. Gallia,et al. Exomic Sequencing of Four Rare Central Nervous System Tumor Types , 2013, Oncotarget.
[33] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[34] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[35] N. Mitra,et al. Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: a SEER analysis , 2012, Journal of Neuro-Oncology.
[36] David T. W. Jones,et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.
[37] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[38] Carlo C. Maley,et al. Clonal evolution in cancer , 2012, Nature.
[39] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.
[40] S. Cannistra,et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. , 2011, Cancer research.
[41] Kirsten Schmieder,et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.
[42] J. Biegel,et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. , 2010, Neuro-oncology.
[43] N. Balak,et al. Anaplastic pleomorphic xanthoastrocytoma , 2009, Child's Nervous System.
[44] A. Hoischen,et al. Frequent loss of chromosome 9, homozygous CDKN2A/p14ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas , 2007, Oncogene.
[45] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[46] P. Ladenson,et al. BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.
[47] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[48] D. Brat,et al. Pleomorphic xanthoastrocytoma , 1999, Cancer.
[49] D. Louis,et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.